Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study

References

• GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–1602.
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2017. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. [cited 2019 Jan 6] Available from: http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.
   Google Scholar
• Milic-Emili J, Pecchiari M, D’ Angelo E. Pathophysiology of chronic obstructive pulmonary disease. Curr Respir Med Rev. 2008;4:249–256.
   Google Scholar
• Tantucci C, Pini L. COPD: it is time to change! Int J Chron Obstruct Pulmon Dis. 2015;10:2451–2457. doi:10.2147/COPD.S87696.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Loukides S, Gourgoulianis KI, et al. Global assessment of the COPD patient: time to look beyond FEV1? Respir Med. 2009;103:650–660. doi:10.1016/j.rmed.2009.01.001.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Hurd S, Anzueto A, Global Initiative for Chronic Obstructive Lung Disease, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555. doi:10.1164/rccm.200703-456SO.
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580–586. doi:10.1378/chest.93.3.580.
   PubMed Web of Science ®Google Scholar
• Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34:648–654. doi:10.1183/09031936.00102509.
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management and prevention of chronic pulmonary disease, 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2011. [cited 2019 Jan 6]. Available from: http://www.goldcopd.org/Guidelines/guidelines-resources.html.
   Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195:557–582. doi:10.1164/rccm.201701-0218PP.
   PubMed Web of Science ®Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2018. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2018. [cited 2019 Jan 6] Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
   Google Scholar
• Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2019. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2019. [cited 2019 Jan 6] Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf
   Google Scholar
• Braido F, Di Marco F, Santus P, et al. COPD classification methods and informativeness on mortality: contrasting evidences. Minerva Med. 2013;104: 1–5.
   PubMedGoogle Scholar
• Leivseth L, Brumpton BM, Nilsen TI, et al. GOLD classifications and mortality in chronic obstructive pulmonary disease: the HUNT Study, Norway. Thorax. 2013;68:914–921. doi:10.1136/thoraxjnl-2013-203270.
   PubMed Web of Science ®Google Scholar
• Cabrera López C, Casanova Macario C, Marín Trigo JM, et al. Comparison of the 2017 and 2015 global initiative for chronic obstructive lung disease reports. Impact on grouping and outcomes. Am J Respir Crit Care Med. 2018;197:463–469. doi:10.1164/rccm.201707-1363OC.
   PubMed Web of Science ®Google Scholar
• Dusser D, Wise RA, Dahl R, et al. Differences in outcomes between GOLD groups in patients with COPD in the TIOSPIR(®) trial. Int J Chron Obstruct Pulmon Dis. 2016;11:133–145. doi:10.2147/COPD.S97924.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Hanagama M, Ishida M, et al. Clinical characteristics and outcomes in Japanese patients with COPD according to the 2017 GOLD classification: the Ishinomaki COPD Network Registry. COPD. 2018;13:3947–3955. doi:10.2147/COPD.S182905.
   Google Scholar
• Bhatt SP, Soler X, Wang X, COPDGene Investigators, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194:178–184. doi:10.1164/rccm.201511-2219OC.
   PubMed Web of Science ®Google Scholar
• Golpe R, Suárez-Valor M, Martín-Robles I, et al. Mortality in COPD patients according to clinical phenotypes. COPD. 2018;13:1433–1439. doi:10.2147/COPD.S159834.
   Google Scholar
• Cosio BG, Soriano JB, López-Campos JL, CHAIN study, et al. Distribution and outcomes of a phenotype-based approach to guide COPD management: results from the CHAIN cohort. PLoS One. 2016;11:e0160770. ;. doi:10.1371/journal.pone.0160770.
   PubMed Web of Science ®Google Scholar
• Barnes NC, Sharma R, Lettis S, et al. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47:1374–1382. doi:10.1183/13993003.01370-2015.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–442. doi:10.1016/S2213-2600(15)00106-X.
   PubMed Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, SPIROMICS investigators, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5:956–967. doi:10.1016/S2213-2600(17)30432-0.
   PubMed Web of Science ®Google Scholar
• Pinto-Plata V, Casanova C, Müllerova H, et al. Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. Respir Res. 2012;13:71. doi:10.1186/1465-9921-13-71.
   PubMed Web of Science ®Google Scholar
• Burrows B, Knudson RJ, Cline MG, et al. Quantitative relationships between cigarette smoking and ventilatory function. Am Rev Respir Dis. 1977;115:195–205. doi:10.1164/arrd.1977.115.2.195.
   PubMed Web of Science ®Google Scholar
• Ohar JA, Sadeghnejad A, Meyers DA, et al. Do symptoms predict COPD in smokers? Chest. 2010;137:1345–1353. doi:10.1378/chest.09-2681.
   PubMed Web of Science ®Google Scholar
• Hansen JE, Sun XG, Wasserman K. Spirometric criteria for airway obstruction: use percentage of FEV1/FVC ratio below the fifth percentile, not <70%. Chest. 2007;131:349–355.
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–968. doi:10.1183/09031936.05.00035205.
   PubMed Web of Science ®Google Scholar
• Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374:733–743. doi:10.1016/S0140-6736(09)61303-9.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Santus P, Radovanovic D, Henchi S, et al. Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir Physiol Neurobiol. 2014;197:36–45. doi:10.1016/j.resp.2014.03.012.
   PubMed Web of Science ®Google Scholar
• Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26:511–522. doi:10.1183/09031936.05.00035005.
   PubMed Web of Science ®Google Scholar
• Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–735. doi:10.1183/09031936.05.00034905.
   PubMed Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993;16:5–40.
   PubMedGoogle Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s.
   PubMedGoogle Scholar
• Pistolesi M, Camiciottoli G, Paoletti M, et al. Identification of a predominant COPD phenotype in clinical practice. Respir Med. 2008;102:367–376. doi:10.1016/j.rmed.2007.10.019.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Pavord I, Hinds D, et al. The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised. Lancet Respir Med. 2018;6:e18doi:10.1016/S2213-2600(18)30137-1.
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivée P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151:366–373. doi:10.1016/j.chest.2016.10.003.
   PubMed Web of Science ®Google Scholar
• Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50:1701162. doi:10.1183/13993003.01162-2017.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193:965–974. doi:10.1164/rccm.201509-1869OC.
   PubMed Web of Science ®Google Scholar
• Cosío BG, Pérez de Llano L, Lopez Viña A, et al. on behalf of the CHACOS study group. Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome?. Eur Respir J. 2017;49:1602397. doi:10.1183/13993003.02397-2016.
   PubMed Web of Science ®Google Scholar
• Tantucci C, Donati P, Nicosia F, et al. Inspiratory capacity predicts mortality in patients with chronic obstructive pulmonary disease. Respir Med. 2008;102:613–619. doi:10.1016/j.rmed.2007.11.004.
   PubMed Web of Science ®Google Scholar
• Celli BR, Decramer M, Lystig T, et al. Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respir Res. 2012;13:66. doi:10.1186/1465-9921-13-66.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Balzano G, et al. Improvements in lung diffusion capacity following pulmonary rehabilitation in COPD with and without ventilation inhomogeneity. Respiration. 2016;92:295–307. doi:10.1159/000448847.
   PubMed Web of Science ®Google Scholar
• Díaz AA, Pinto-Plata V, Hernández C, et al. Emphysema and DLCO predict a clinically important difference for 6MWD decline in COPD. Respir Med. 2015;109:882–889. doi:10.1016/j.rmed.2015.04.009.
   PubMed Web of Science ®Google Scholar
• Pecchiari M, Radovanovic D, Santus P, et al. Airway occlusion assessed by single breath N2 test and lung P-V curve in healthy subjects and COPD patients. Respir Physiol Neurobiol. 2016;234:60–68. doi:10.1016/j.resp.2016.09.006.
   PubMed Web of Science ®Google Scholar
• Lahousse L, Seys LJM, Joos GF, et al. Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease. Eur Respir J. 2017;50:1602470. doi:10.1183/13993003.02470-2016.
   PubMed Web of Science ®Google Scholar
• Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:44–52. doi:10.1164/rccm.201106-0992OC.
   PubMed Web of Science ®Google Scholar
• Safka KA, Wald J, Wang H, et al. GOLD stage and treatment in COPD: A 500 patient point prevalence study. Chronic Obstr Pulm Dis. 2016;4:45–55. doi:10.15326/jcopdf.4.1.2016.0126.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. UPLIFT study investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543–1554. doi:10.1056/NEJMoa0805800.
   PubMed Web of Science ®Google Scholar
• Doyle AD, Mukherjee M, LeSuer WE, et al. Eosinophil-derived IL-13 promotes emphysema. Eur Respir J. 2019;53:1801291. doi:10.1183/13993003.01291-2018.
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Magnussen H, Miravitlles M, et al. Triple therapy in COPD: what we know and what we don't. COPD. 2017;14:648–662. doi:10.1080/15412555.2017.1389875.
   PubMedGoogle Scholar
• Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150:320–328. doi:10.1016/j.chest.2016.01.026.
   PubMed Web of Science ®Google Scholar
• Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. COPD. 2017;12:1819–1824. doi:10.2147/COPD.S129787.
   Google Scholar
• Glaab T, Vogelmeier C, Hellmann A, et al. Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany. Int J Chron Obstruct Pulmon Dis. 2012;7:101–108.
   PubMed Web of Science ®Google Scholar
• Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med. 2012;106:989–997. doi:10.1016/j.rmed.2012.03.008.
   PubMed Web of Science ®Google Scholar
• Contoli M, Corsico AG, Santus P, et al. Use of ICS in COPD: from blockbuster medicine to precision medicine. COPD. 2017;14:641–647. doi:10.1080/15412555.2017.1385056.
   PubMedGoogle Scholar
• Tudoric N, Koblizek V, Miravitlles M, et al. GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort. Eur Respir J. 2017;49:1602518. doi:10.1183/13993003.02518-2016.
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Crimi E, Gobbi A, et al. Severity grading of chronic obstructive pulmonary disease: the confounding effect of phenotype and thoracic gas compression. J Appl Physiol (1985). 2015;118:796–802. doi:10.1152/japplphysiol.00801.2014.
   PubMed Web of Science ®Google Scholar
• Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet. 1966;1:830–835. doi:10.1016/S0140-6736(66)90181-4.
   PubMed Web of Science ®Google Scholar